ArticleAnalytical chemistry2026
Acoustofluidic Plasmapheresis System Designed for Ultralow Blood Volume Applications.
Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present an integrated acoustofluidic plasmapheresis system designed for ultralow blood volume applications, such as neonatal care, enabling in-line sampling and plasma separation from whole blood. The system combines a two-stage acoustophoresis chip with microperistaltic pumps and PDMS-based flow pulsation dampeners to ensure continuous, stable operation. The input whole blood is acoustically separated into a cell-free plasma fraction and a returnable cell fraction, enabling closed-loop operation for neonates who have a circulating blood volume as low as 50 mL. The system achieves a plasma generation rate of 27.5 μL/min with ∼100% cell removal, outperforming previous microfluidic plasma separation approaches in terms of purity, throughput, and minimal sample volume. Plasma quality was validated by quantifying hemolysis and residual cellular content, while system robustness was demonstrated across hematocrit levels up to 50%, which is close to the average upper hematocrit value in neonates. Compared to previous microfluidic techniques, our system achieves the fastest generation of clinical quality undiluted plasma with the lowest required blood volume, making it highly suitable for point-of-care integration in neonatal intensive care units.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.